-
The Ernst Vioxx Verdict: A Retrospective Look Into the Jury Room, Part One
The Ernst v. Merck Jury: On Sending a Message to Merck and Big Pharma The Association of Trial Lawyers of America ("ATLA"), of which I am a proud member, has compiled selected statements made…
-
Scios / J&J to Educate Doctors Regarding Which Patients Should, and Should Not, Receive Natrecor
Guidance to Doctors Prompted by Natrecor Expert Panel or US DOJ Investigation of Sales Tactics? Johnson & Johnson’s Scios unit announced on August 22, 2005 the launch of a new program intended to educate…
-
New Drug Safety Panel Will Mean More FDA Scrutiny of Drugs Already on Market, But Perhaps Not Enough
Congress Should Give FDA Authority to Impose New Labeling Language on Approved Drugs Without Needing Big Pharma’s Permission When Health and Human Services (HHS) Secretary Michael Leavitt was announcing the new Drug Safety Oversight…
-
Upcoming Vioxx Trials: The Fall 2005 Line-up for Merck and Its Lawyers
A Summary of the Vioxx Lawsuits Coming Soon in New Jersey, Texas, and Louisiana As is well-known by now, Merck & Co. lost its first Vioxx trial in a Texas state court last week,…
-
Patients Discharged From Hospital Often Lack Sufficient Knowledge About Their Medications
Drug-safety Issue: Prescription Medication Noncompliance Due to Patient Misunderstanding In the August 2005 issue of Mayo Clinic Proceedings (Mayo Clin Proc 2005;80:991-994) a small study report suggests that poor communication with patients when being…
-
Ernst v. Merck Vioxx Trial: Massive Verdict for Plaintiff; Knock-out Punch for Merck?
Merck Vows to Fight All Comers Despite Texas Jury’s Condemnation of Vioxx to Tune of $253 Million On August 19, 2005 Merck & Co. was found negligent in the nation’s first Vioxx trial, Carol…
